Summary
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
History
Onconova Therapeutics was founded in 2003 to develop novel treatments for people with cancer. In 2008 the company achieved its first regulatory filing for an investigational new drug (IND). This IND was for Rigosertib (ON 01210.Na), a protein kinase inhibitor, which has been developed for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Since then, the company has filed additional INDs and opened several clinical trials in the United States and abroad using the Rigosertib platform.
Mission
Onconova Therapeutics is committed to transforming the treatment of cancer through the research, development and commercialization of drugs to treat hematological and solid tumor malignancies.
Vision
Onconova Therapeutics strives to be a leader in developing innovative treatments for people with cancer by providing life-saving and life-enhancing therapies that can improve quality of life.
Key Team
Dr. Mark Stephen Gelder M.D. (Chief Medical Officer)
Recognition and Awards
Onconova Therapeutics has received numerous awards, including a Global Start-up Award from the European Federation of Biotechnology and a 'Breakthrough of the Year Award' from the Japanese Association for Cancer Research. In 2012, the company's Rigosertib clinical trial study was named an 'Acutis Project' by the International Myeloma Society. The company was also recognized by the US National Cancer Institute in 2013 as a National Cancer Institute Small Business Innovation Research recipient.
References
United States 